For the first time, we demonstrated that SPANXB1 can upregulate MMP1 by modulating YY1 and histone H3R17me2 modifications, thus providing a novel insight into the role of SPANXB1 as a chromatin-binding protein and its potential as a therapeutic target for managing tumor metastasis. Here, YY1 is linked to neoplasm.